SEARCH

SEARCH BY CITATION

References

  • 1
    Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001; 120: 150217.
  • 2
    Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40: 64652.
  • 3
    Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 84857.
  • 4
    Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000; 45: 19448.
  • 5
    Ryder SD, Koskinas J, Rizzi PM, et al. Hepatocellular carcinoma complicating autoimmune hepatitis: role of hepatitis C virus. Hepatology 1995; 22: 71822.
  • 6
    Yamazaki K, Kamiyama T, Shiba S, et al. An aged male patient with autoimmune hepatitis complicated by hepatocellular carcinoma. Intern Med 1999; 38: 4225.
  • 7
    Watanabe M, Moritani M, Hamamoto S, et al. Hepatocellular carcinoma complicating HCV-negative autoimmune hepatitis without corticosteroid therapy. J Clin Gastroenterol 2000; 30: 4456.
  • 8
    Hori K, Fukuda Y, Tomita T, et al. Hepatocellular carcinoma complicating autoimmune hepatitis without either hepatitis C viral infection or corticosteroid therapy. J Gastroenterol 2003; 38: 1979.
  • 9
    Hardee JT, Breth GF, El-Serag HB. Hepatocellular carcinoma associated with autoimmune hepatitis. J Clin Gastroenterol 2003; 37: 2712.
  • 10
    Sakaguchi T, Nakamura S, Suzuki S, et al. Hepatocellular carcinoma associated with lupoid hepatitis: a review of Japanese reports. Surg Today 1995; 25: 83842.
  • 11
    Nishiyama R, Kanai T, Abe J, et al. Hepatocellular carcinoma associated with autoimmune hepatitis. J Hepatobiliary Pancreat Surg 2004; 11: 2159.
  • 12
    Miyake Y, Sakaguchi K, Tanaka H, et al. Development of hepatocellular carcinoma in a woman with HBV- and HCV-negative autoimmune hepatitis with unsatisfactory response to corticosteroid. Intern Med 2005; 44: 94953.
  • 13
    Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005; 43: 9517.
  • 14
    Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005; 42: 5362.
  • 15
    Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 92938.
  • 16
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 151320.
  • 17
    Schvarcz R, Glaumann H, Weiland O. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis. J Hepatol 1993; 18: 1523.
  • 18
    Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 15106.
    Direct Link:
  • 19
    Milkiewicz P, Ahmed M, Hathaway M, Elias E. Factors associated with progression of the disease before transplantation in patients with autoimmune hepatitis. Liver 1999; 19: 504.
  • 20
    Hino T, Kumashiro R, Ide T, et al.; Autoimmune Hepatitis Study Group. Predictive factors for remission and death in 73 patients with autoimmune hepatitis in Japan. Int J Mol Med 2003; 11: 74955.
  • 21
    Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 2005; 50: 54751.
  • 22
    Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 4905.
  • 23
    Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999; 30: 13816.
  • 24
    Saeian K, Franco J, Komorowski RA, Adams MB. Hepatocellular carcinoma after renal transplantation in the absence of cirrhosis or viral hepatitis: a case series. Liver Transpl Surg 1999; 5: 469.
  • 25
    Cattan S, Wendum D, Chazouilleres O, Schmitz J, Gendre JP. Hepatocellular carcinoma and focal hepatic glycogenosis after prolonged azathioprine therapy. Hum Pathol 2000; 31: 8746.
  • 26
    Russmann S, Zimmermann A, Krahenbuhl S, Kern B, Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 2001; 13: 28790.
  • 27
    Borum ML. Unusual development of hepatocellular carcinoma in a patient with Crohn's disease. Dig Dis Sci 2001; 46: 2199200.
  • 28
    Czaja AJ, Freese DK; American Association for the Study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 47997.